Sign Up to like & get
recommendations!
0
Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-119559
Abstract: Background: Staging systems, which help define prognosis and influence treatment decisions, for myeloma have evolved. The Durie-Salmon system (DS) was based largely on perceived myeloma cell tumor burden. In 2005, the International Staging System (ISS)…
read more here.
Keywords:
consultancy;
consultancy honoraria;
speakers bureau;
documentation ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-120184
Abstract: Introduction: CMML is a myeloid neoplasm hallmarked by cytopenias and a peripheral monocytosis. Although uniformly fatal, many patients (pts) are diagnosed incidentally and are monitored without treatment. Therapy is implemented when symptomatic cytopenias, splenomegaly, or…
read more here.
Keywords:
amc;
speakers bureau;
cmml;
consultancy ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-128486
Abstract: Background: The availability of factor (F)VIII replacement products has dramatically improved life expectancy for patients with hemophilia A (HA). However, older patients face distinct challenges. Age-related comorbidities such as cardiovascular disease (CVD), often involving treatments…
read more here.
Keywords:
consultancy honoraria;
consultancy speakers;
speakers bureau;
consultancy ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-137398
Abstract: Corticosteriods (CSs) remain the standard of care for immune thrombocytopenia (ITP); however, many patients relapse after initial treatment, and long-term CS use is associated with considerable toxicity and tolerability issues (Provan et al. Blood 2010).…
read more here.
Keywords:
treatment;
sustained response;
speakers bureau;
honoraria speakers ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-139239
Abstract: Assessment of the role of genetic abnormalities and minimal residual disease (MRD) is an active developing area in hematology. The use of genetic methods makes it possible to predict the course of the disease and…
read more here.
Keywords:
mrd;
months mrd;
speakers bureau;
mrd group ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-139418
Abstract: Background: Rapid progress in next-generation sequencing (NGS) technologies make it possible to spell out the mutational status, the genetic and epigenetic variability of chronic lymphocytic leukemia (CLL). The identification of driver mutations allows us to…
read more here.
Keywords:
cll;
mutational status;
speakers bureau;
honoraria speakers ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "Blood"
DOI: 10.1182/blood-2021-153742
Abstract: Introduction Introduction of imatinib and other tyrosine kinase inhibitors (TKIs) dramatically improved the quality of life (QoL) of patients with chronic myeloid leukemia (CML). However, the impact of Covid-19 on the QoL of patients with…
read more here.
Keywords:
speakers bureau;
vaccination;
health;
honoraria speakers ... See more keywords